Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Biotechnology

Healthcare
$149.40 -2.22%

-$6.27 today

Market cap
$20.01B
Beta
0.27
P/E (TTM)
63.6
EPS (TTM)
$4.34
52W Low $273.11High $495.55

Volume 2.52M

Average 1.11M

ALNY Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Alnylam Pharmaceuticals, Inc.NASDAQ: ALNY

Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026

Stock-based compensation dips below year-ago levels

Q2 FY2026 stock-based compensation of $86.63M fell 22.4% year over year, behind the +10.1% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 23.5% from the prior quarter. Over 3 fiscal years it compounded at +14.7% a year.

Context

  • Stock-based compensation amounted to 9.4% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -22.4% toward the trailing-twelve-month pace of +10.1%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$86.63M+23.5% QoQ
Last fiscal yearDec 2025
$348.24M+28.0% YoY
LTMJun 2026
$336.62M+10.1% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-22.4%——
1 year+28.0%——
3-year CAGR+14.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
348.24M USD
Year-over-year change
+28.0%
4-year CAGR
+20.4%

Stock-Based Compensation vs competitors

How ALNY compares with its peers on the latest reported figures

  • ALNY's LTM Jun 2026 stock-based compensation of $336.62M is the largest of the 6 companies compared; the peer median is $68.15M.
  • Its year-over-year change of +10.1% is the 2nd highest of 5, against a peer median of +6.0%.
  • Stock-based compensation amounts to 7.0% of revenue for ALNY, versus a peer median of 30.3%.
ALNY Competitors Peer median
Stock-Based Compensation for ALNY and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$336.62M +10.1%+14.7%7.0%
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$145.91M +2.8%+19.1%220.8%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$132.29M +4.4%+10.1%13.8%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$68.15M +7.5%-4.5%15.1%
WVEWave Life Sciences Ltd.LTM Mar 2026$21.73M +42.8%—30.3%
SLNSilence Therapeutics plcLTM Mar 2026$14.34M —-14.0%1556.3%
Peer median (excluding ALNY) $68.15M+6.0%+2.8%30.3%

Competitors are the stored peer set for ALNY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(852.82M)(1.13B)(440.24M)(278.16M)313.75M
Depreciation & Amortization47.57M44.47M54.05M56.67M55.66M
Deferred Income Tax(55.7M)00(106.76M)(2.2M)
Stock-Based Compensation165.72M230.65M221.68M272.08M348.24M
Change in Working Capital(162.82M)(35.55M)10.76M(214.08M)(444.78M)
Accounts Receivables(101.8M)(45.6M)(87.94M)(86.55M)(359.96M)
Inventory(26.42M)(34.14M)18.37M13.59M8.47M
Accounts Payables88.24M191.77M80.84M91.09M75.07M
Other Working Capital(122.85M)(147.59M)(509K)(232.22M)(168.36M)
Other Non-Cash Items216.37M350.32M257.91M261.94M253.42M
Operating Cash Flow(641.69M)(541.27M)104.16M(8.31M)524.08M
Capital Expenditures(76.37M)(72.06M)(62.21M)(34.28M)(58.7M)
Acquisitions (Net)00000
Purchases of Investments(1.66B)(1.98B)(1.82B)(1.71B)(1.36B)
Sales of Investments1.46B2.23B1.55B1.57B1.8B
Other Investing Activities(4.36M)(13.19M)(4.44M)57.76M57.63M
Investing Cash Flow(273.3M)169.35M(336.35M)(116.84M)436.33M
Debt Repayment500M254M00(546.95M)
Common Stock Issued246.27M259.36M147.46M302.95M250.03M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities500.85M(87.61M)24.67M(8.79M)(8.27M)
Financing Cash Flow1.25B425.75M172.13M294.16M(305.19M)
Effect of Forex Changes(9.02M)(7.43M)6.39M(15.24M)34.94M
Net Change in Cash323.11M46.4M(53.67M)153.77M690.16M
Free Cash Flow(718.07M)(613.33M)41.95M(42.59M)465.38M

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Intrinsic Alpha fair value

Locked

Current Price

$149.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.